|
Press Releases |
|
 |
|
Wednesday, March 30, 2016 |
|
Eisai Co., Ltd. and Ajinomoto Co., Inc. Announce Establishment of Gastrointestinal Specialty Pharma EA Pharma Co., Ltd. |
Eisai Co., Ltd. and Ajinomoto Co., Inc. announced today that based on the integration agreement signed and announced on October 15, 2015, the gastrointestinal specialty pharma EA Pharma Co., Ltd. will be established through the splitting off of a portion of Eisai's gastrointestinal disease treatment. more info >> |
|
Eisai's Notification Regarding Revision of Consolidated Financial Results Forecasts (IFRS) for the Fiscal Year Ending March 31, 2016 |
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that based on recent trends in business results, etc., the company has revised its full-year consolidated financial results forecasts for the fiscal year ending March 31, 2016 (April 1, 2015 to March 31, 2016) previously announced on February 2, 2016. more info >> |
|
Eisai's Notice Concerning Shelf Registration for Issuance of Stock Options |
Eisai Co., Ltd. ("the Company") today filed a shelf registration statement with the Kanto Local Finance Bureau for issuance of stock options in accordance with the Company's "Policy for Protection of the Company's Corporate Value and Common Interests of Shareholders" ("the Policy"). more info >> |
|
Tuesday, March 29, 2016 |
|
Eisai's In-House Developed Antiepileptic Drug Fycompa (Perampanel Hydrate) Approved in Japan |
Eisai Co., Ltd. announced today that its in-house-discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) has been approved in Japan as an adjunctive therapy for partial-onset seizures or primary generalized tonic-clonic seizures in patients with epilepsy showing inadequate response to other AEDs. more info >> |
|
Tuesday, March 22, 2016 |
|
Eisai Withdraws New Drugs Application for Mecobalamin Ultra-High Dose Preparation as Treatment for Amyotrophic Lateral Sclerosis |
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has withdrawn its new drug application for ultra-high dose Mecobalamin development code: E0302) as a treatment for amyotrophic lateral sclerosis (ALS) in Japan. more info >> |
|
Thursday, March 17, 2016 |
|
Notice Regarding Discontinuation of Sales and Voluntary Recall of Egg White Lysozyme Preparation Neuzym |
Eisai Co., Ltd. announced today that its pharmaceutical manufacturing and marketing subsidiary Sannova Co., Ltd. has been informed the results of deliberation of the Committee on Reevaluation of the Pharmaceutical Affairs and Food Sanitation Council's meeting held on March 17 regarding the egg white lysozyme preparation Neuzym (lysozyme hydrochloride, "lysozyme") which had been submitted for reevaluation. more info >> |
|
Monday, February 15, 2016 |
|
Eisai and Sysmex Enter Comprehensive Agreement to Create Next-Generation Diagnostic Reagents in the Field of Dementia |
Eisai Co., Ltd. and Sysmex Corporation jointly announced that the two companies have entered into a comprehensive non-exclusive collaboration agreement aimed at the creation of new diagnostics in the field of dementia. more info >> |
|
Friday, February 12, 2016 |
|
Phase III Trial Results of Eisai's Anticancer Agent Halaven(R) in Soft Tissue Sarcoma Published in The Lancet |
Eisai Co., Ltd. announced today that the results of a Phase III clinical study (Study 309) of its in-house discovered and developed anticancer agent Halaven(R) (eribulin mesylate) in patients with locally advanced, recurrent or metastatic soft tissue sarcoma (liposarcoma or leiomyosarcoma)[1] have been published in the online version of The Lancet. more info >> |
|
Monday, February 1, 2016 |
|
Eisai Acquires Exclusive License from Huya Bioscience International to Develop and Market HDAC Inhibitor HBI-8000 in Japan and Other Asian Countries |
Eisai Co., Ltd. (TSE:4523) announced today that Eisai has entered into an exclusive license agreement with HUYA Bioscience International, LLC (San Diego, CA, USA) to develop and market the oral histone deacetylase (HDAC) inhibitor HBI-8000 in Japan, South Korea, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Singapore. more info >> |
|
Tuesday, January 12, 2016 |
|
Eisai Submits New Application in Europe for In-House Developed Anticancer Agent Lenvatinib Seeking Approval for Indication Covering Renal Cell Carcinoma |
Eisai Co., Ltd. announced today that its European regional headquarters Eisai Europe Ltd. (Location: U.K.) has submitted a new application to the European Medicines Agency (EMA) for its in-house developed novel anticancer agent lenvatinib mesylate for use in the treatment of advanced or metastatic renal cell carcinoma. more info >> |
|
|
|
|
|
|
|
|
 |
Latest Press Releases |
 |
Global Crypto Leaders to Converge in Dubai for Historic 30th Edition of HODL
May 9, 2025 23:16 HKT/SGT
|
|
|
Nestle and OMP Showcase Approach to Future-Ready Supply Chain at Gartner Supply Chain Symposium/Xpo in Barcelona
May 9, 2025 22:00 HKT/SGT
|
|
|
UK Certifies Protector As First of Its Kind Remotely Piloted Aircraft
May 9, 2025 22:00 HKT/SGT
|
|
|
ZA Miner Expands Cloud Mining Platform with Clean Energy Infrastructure and Increased Global Adoption
May 9, 2025 20:00 HKT/SGT
|
|
|
Mitsubishi Heavy Industries Achieves Highest-Ever Order Intake, Revenue, Net Income, and Free Cash Flow in FY2024, Increases Dividends, and Releases FY2025 Guidance
May 9, 2025 18:57 JST
|
|
|
Valuufy Selected by Global Tech Leader for Environmental Impact Assessment
May 9, 2025 18:00 JST
|
|
|
Guangzhou Electrical Building Technology 2025 brings industry leaders together to shape a low-carbon, intelligent building future
May 9, 2025 17:00 HKT/SGT
|
|
|
DigiTech ASEAN Thailand Returns this November as Demands for Digital and AI-Driven Solutions Grow
May 9, 2025 16:45 HKT/SGT
|
|
|
Thailand, Led by DPM Prasert, to Showcase Leadership in Hosting the 3rd UNESCO Global Forum on the Ethics of AI 2025
May 9, 2025 15:30 HKT/SGT
|
|
|
Mazda Adopts North American Charging Standard for BEVs launched in Japan
May 9, 2025 16:03 JST
|
|
|
Solar & Storage Live Philippines 2025 Powers Up to Drive the Nation's Clean Energy Future
May 9, 2025 14:28 HKT/SGT
|
|
|
Ensign InfoSecurity Recognised in MITRE's 2024 Impact Report for Contribution to Global Cyber Defence Research
May 9, 2025 11:00 HKT/SGT
|
|
|
Unlocking the Full Potential of GCCs: The Strategic Power of Cultural Integration
May 9, 2025 02:53 HKT/SGT
|
|
|
India: Revolutionizing Video And Content For The Global Media And Entertainment Industy
May 9, 2025 02:14 HKT/SGT
|
|
|
The 33rd China Cycle 2025 Grandly Commences
May 8, 2025 17:00 HKT/SGT
|
|
|
|
More Press release >> |
|
|
 |
 |
 |
|
|